Journal of Infection and Public Health最新文献

英文中文

Epidemiology of hepatitis C in Alberta, Saskatchewan, and Manitoba compared to Canada, 1980–2023 1980-2023年艾伯塔省、萨斯喀彻温省和马尼托巴省丙型肝炎流行病学与加拿大比较

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-09 DOI: 10.1016/j.jiph.2026.103148

Zipporah Gitau , Camilo Suarez-Ariza , Maria Arango-Uribe , Mariana Herrera-Diaz , Camila Oda , Angela Copete , Rotem Keynan , Ameeta E. Singh , Stuart Skinner , Cara Spence , Lauren J. MacKenzie , Ken Kasper , Laurie Ireland , Jared Bullard , Lucelly Lopez , Diana Marin , Margaret Haworth-Brockman , Zulma Vanessa Rueda , Yoav Keynan

Background

Canada aims to eliminate hepatitis C (HCV) by 2030. While national rates have dropped, regional disparities persist. In 2021, Manitoba had the highest new HCV rates, and Saskatchewan's rates were double the national average. This study aimed to describe the incidence and risk factors associated with HCV infections in Alberta, Saskatchewan, and Manitoba, compared to Canada,1980–2023.

Methods

This ecological study used publicly available government reports from Alberta, Saskatchewan, Manitoba, and Canada (1980–2023) on HCV cases and rates by year and disaggregated by sex (female/male), age, ethnicity, province, sexual orientation (gay/bisexual men who have sex with men, heterosexual), and risk factors (injection drug use, blood products, and history of incarceration).

Results

Since becoming nationally notifiable in 1991, HCV incidence in Canada has declined, but Saskatchewan has reported consistently rates above the national average since 2005. Manitoba's incidence rose, peaking in 2018, with the highest national rate in 2021 (42.8/100,000), while Alberta had the lowest rate (14.5/100,00 people). Males represented 61 % of HCV cases in Canada in 2022, but the sex gap is narrowing, particularly in the Prairies. Most cases in Canada occur among individuals aged 40–59, but younger groups (20–39) are increasingly affected in the Prairies, particularly females of childbearing age and males aged 30–39. Injection drug use was the leading risk factor in Saskatchewan and Manitoba.

Conclusion

Canada is on a downward trend in rates of HCV; however, Manitoba and Saskatchewan have higher rates, possibly due to syndemics of substance use, which are leading to increased rates of HIV and STBBIs. A collaborative effort in surveillance, testing, treatment, and prevention of HCV across the three provinces is necessary.

加拿大旨在到2030年消除丙型肝炎（HCV）。虽然全国的比率有所下降，但地区差异依然存在。2021年，曼尼托巴省的新丙肝病毒感染率最高，萨斯喀彻温省的新丙肝病毒感染率是全国平均水平的两倍。本研究旨在描述1980-2023年与加拿大相比，阿尔伯塔省、萨斯喀彻温省和马尼托巴省HCV感染的发病率和相关危险因素。方法本生态研究使用了阿尔伯塔省、萨斯喀彻温省、马尼托巴省和加拿大（1980-2023年）公开的政府报告，按性别（女性/男性）、年龄、种族、省份、性取向（男同性恋/双性恋男性、异性恋）和危险因素（注射药物使用、血液制品和监禁史）分类，并按年统计了HCV病例和发病率。结果自1991年成为全国报告以来，加拿大的HCV发病率有所下降，但萨斯喀彻温省自2005年以来报告的发病率一直高于全国平均水平。曼尼托巴省的发病率上升，在2018年达到顶峰，2021年全国发病率最高（42.8/10万人），而阿尔伯塔省的发病率最低（14.5/10万人）。2022年，男性占加拿大HCV病例的61% %，但性别差距正在缩小，特别是在大草原地区。在加拿大，大多数病例发生在40-59岁的人群中，但在草原地区，越来越多的年轻群体（20-39岁）受到影响，尤其是育龄女性和30-39岁的男性。注射吸毒是萨斯喀彻温省和马尼托巴省的主要危险因素。结论加拿大HCV感染率呈下降趋势；然而，马尼托巴省和萨斯喀彻温省的比率较高，可能是由于药物使用综合症，这导致艾滋病毒和性传染感染的比率上升。这三个省必须在监测、检测、治疗和预防丙肝病毒方面开展合作。

{"title":"Epidemiology of hepatitis C in Alberta, Saskatchewan, and Manitoba compared to Canada, 1980–2023","authors":"Zipporah Gitau , Camilo Suarez-Ariza , Maria Arango-Uribe , Mariana Herrera-Diaz , Camila Oda , Angela Copete , Rotem Keynan , Ameeta E. Singh , Stuart Skinner , Cara Spence , Lauren J. MacKenzie , Ken Kasper , Laurie Ireland , Jared Bullard , Lucelly Lopez , Diana Marin , Margaret Haworth-Brockman , Zulma Vanessa Rueda , Yoav Keynan","doi":"10.1016/j.jiph.2026.103148","DOIUrl":"10.1016/j.jiph.2026.103148","url":null,"abstract":"<div><h3>Background</h3><div>Canada aims to eliminate hepatitis C (HCV) by 2030. While national rates have dropped, regional disparities persist. In 2021, Manitoba had the highest new HCV rates, and Saskatchewan's rates were double the national average. This study aimed to describe the incidence and risk factors associated with HCV infections in Alberta, Saskatchewan, and Manitoba, compared to Canada,1980–2023.</div></div><div><h3>Methods</h3><div>This ecological study used publicly available government reports from Alberta, Saskatchewan, Manitoba, and Canada (1980–2023) on HCV cases and rates by year and disaggregated by sex (female/male), age, ethnicity, province, sexual orientation (gay/bisexual men who have sex with men, heterosexual), and risk factors (injection drug use, blood products, and history of incarceration).</div></div><div><h3>Results</h3><div>Since becoming nationally notifiable in 1991, HCV incidence in Canada has declined, but Saskatchewan has reported consistently rates above the national average since 2005. Manitoba's incidence rose, peaking in 2018, with the highest national rate in 2021 (42.8/100,000), while Alberta had the lowest rate (14.5/100,00 people). Males represented 61 % of HCV cases in Canada in 2022, but the sex gap is narrowing, particularly in the Prairies. Most cases in Canada occur among individuals aged 40–59, but younger groups (20–39) are increasingly affected in the Prairies, particularly females of childbearing age and males aged 30–39. Injection drug use was the leading risk factor in Saskatchewan and Manitoba.</div></div><div><h3>Conclusion</h3><div>Canada is on a downward trend in rates of HCV; however, Manitoba and Saskatchewan have higher rates, possibly due to syndemics of substance use, which are leading to increased rates of HIV and STBBIs. A collaborative effort in surveillance, testing, treatment, and prevention of HCV across the three provinces is necessary.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"19 3","pages":"Article 103148"},"PeriodicalIF":4.0,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in Streptococcus pneumoniae serotypes and antimicrobial resistance in Italy (2007–2023): A mixed-effects model analysis of invasive pneumococcal disease 意大利肺炎链球菌血清型和抗菌素耐药性趋势（2007-2023）：侵袭性肺炎球菌疾病的混合效应模型分析

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-09 DOI: 10.1016/j.jiph.2026.103145

Irene Amoruso , Marco Fonzo , Simone Agostini , Francesca Russo , Vincenzo Baldo , Tatjana Baldovin , Chiara Bertoncello

Introduction

Invasive pneumococcal disease (IPD) remains a significant public health concern despite the widespread implementation of pneumococcal conjugate vaccines (PCVs). Shifts in serotype distribution and antimicrobial resistance (AMR) patterns, particularly in the post-PCV13 era, necessitate ongoing surveillance to inform vaccine and treatment policies.

Methods

We conducted a retrospective analysis of laboratory-confirmed IPD cases reported in the Veneto Region of north-eastern Italy between 2007 and 2023. Data were obtained from regional surveillance systems and included serotype, clinical presentation, demographics, and antimicrobial susceptibility. Trends in IPD incidence were modelled using negative binomial generalised linear mixed models (GLMM). Serotype distribution and AMR patterns were examined over time and in relation to age, sex, and clinical syndrome.

Results

A total of 59 pneumococcal serotypes were identified. Serotype 3 was most frequent, followed by 8 and 19 A. Significant increases were observed for serotype 8, while vaccine-included serotypes (e.g., 6 A, 23 F, 7 F) declined. AMR remained stable overall, with erythromycin and clindamycin resistance observed in 17.3 % and 13.2 % of isolates, respectively. Resistance was concentrated in serotypes 14, 15 A, and 19 A. Serotype 8 showed high prevalence but low resistance rates. The overall IPD incidence remained stable; however, a modest upward trend was observed in pre-COVID19 pandemic years.

Conclusion

Our findings highlight the evolving pneumococcal landscape in the post-PCV13 era, with emerging serotypes contributing significantly to IPD burden. The observed serotype-specific AMR patterns underscore the importance of integrated surveillance to support regionally tailored immunisation strategies and empirical therapy choices. Expanded-valency vaccines may offer broader protection against emerging serotypes.

尽管肺炎球菌结合疫苗（pcv）得到广泛应用，但侵袭性肺炎球菌病（IPD）仍然是一个重大的公共卫生问题。血清型分布和抗菌素耐药性（AMR）模式的变化，特别是在pcv13后时代，需要持续监测，以便为疫苗和治疗政策提供信息。方法回顾性分析意大利东北部威尼托地区2007 - 2023年报告的IPD实验室确诊病例。数据来自区域监测系统，包括血清型、临床表现、人口统计学和抗菌药物敏感性。IPD发病率趋势采用负二项广义线性混合模型（GLMM）建模。血清型分布和AMR模式随时间的推移以及与年龄、性别和临床综合征的关系进行了检查。结果共检出59种肺炎球菌血清型。血清3型发病最多，其次为8例和19例 A。血清8型显著增加，而包含疫苗的血清型（例如6 A、23 F、7 F）下降。抗菌素耐药性总体保持稳定，对红霉素和克林霉素的耐药性分别为17.3% %和13.2 %。耐药集中在14、15 A和19 A血清型。血清8型患病率高，但耐药率低。总体IPD发病率保持稳定；然而，在2019冠状病毒病大流行前的年份，出现了小幅上升趋势。结论：我们的研究结果强调了后pcv13时代肺炎球菌格局的演变，新出现的血清型对IPD负担有重要影响。观察到的血清型特异性抗菌素耐药性模式强调了综合监测的重要性，以支持区域量身定制的免疫策略和经验性治疗选择。扩展价疫苗可能对新出现的血清型提供更广泛的保护。

{"title":"Trends in Streptococcus pneumoniae serotypes and antimicrobial resistance in Italy (2007–2023): A mixed-effects model analysis of invasive pneumococcal disease","authors":"Irene Amoruso , Marco Fonzo , Simone Agostini , Francesca Russo , Vincenzo Baldo , Tatjana Baldovin , Chiara Bertoncello","doi":"10.1016/j.jiph.2026.103145","DOIUrl":"10.1016/j.jiph.2026.103145","url":null,"abstract":"<div><h3>Introduction</h3><div>Invasive pneumococcal disease (IPD) remains a significant public health concern despite the widespread implementation of pneumococcal conjugate vaccines (PCVs). Shifts in serotype distribution and antimicrobial resistance (AMR) patterns, particularly in the post-PCV13 era, necessitate ongoing surveillance to inform vaccine and treatment policies.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of laboratory-confirmed IPD cases reported in the Veneto Region of north-eastern Italy between 2007 and 2023. Data were obtained from regional surveillance systems and included serotype, clinical presentation, demographics, and antimicrobial susceptibility. Trends in IPD incidence were modelled using negative binomial generalised linear mixed models (GLMM). Serotype distribution and AMR patterns were examined over time and in relation to age, sex, and clinical syndrome.</div></div><div><h3>Results</h3><div>A total of 59 pneumococcal serotypes were identified. Serotype 3 was most frequent, followed by 8 and 19 A. Significant increases were observed for serotype 8, while vaccine-included serotypes (e.g., 6 A, 23 F, 7 F) declined. AMR remained stable overall, with erythromycin and clindamycin resistance observed in 17.3 % and 13.2 % of isolates, respectively. Resistance was concentrated in serotypes 14, 15 A, and 19 A. Serotype 8 showed high prevalence but low resistance rates. The overall IPD incidence remained stable; however, a modest upward trend was observed in pre-COVID19 pandemic years.</div></div><div><h3>Conclusion</h3><div>Our findings highlight the evolving pneumococcal landscape in the post-PCV13 era, with emerging serotypes contributing significantly to IPD burden. The observed serotype-specific AMR patterns underscore the importance of integrated surveillance to support regionally tailored immunisation strategies and empirical therapy choices. Expanded-valency vaccines may offer broader protection against emerging serotypes.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"19 3","pages":"Article 103145"},"PeriodicalIF":4.0,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145977895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in dengue incidence and disease burden in South Asia with special reference to India: Insights from the global burden of disease data, 1990–2021 南亚登革热发病率和疾病负担趋势，特别是印度：1990-2021年全球疾病负担数据的见解。

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-09 DOI: 10.1016/j.jiph.2026.103142

Ravichandiran Velayutham , Sheetal Kalra , Sheetal Yadav , Abhishek Dadhich , Prabodh Chander Sharma , Sapna Yadav , Palka Mittal , Aditya Kukreti , Priyansh Ajmera , Puneeta Ajmera , Mohammad Miraj , Riyaz Ahamed Shaik , Abeer Al-Maamari

Background

Dengue fever has become a significant public health issue worldwide, especially in tropical and subtropical regions. In 2000, 505,430 cases of dengue were reported worldwide, and by 2023, the number of cases had increased to nearly 6.5 million. The present study aims to examine the temporal trends in dengue incidence and disability-adjusted life years from 1990 to 2021 using Global Burden of Disease 2021 data across South Asian countries while identifying geographic, gender, and age-related disparities with a specific focus on trends and spatial variations in India.

Methods

The GBD 2021 database was used to extract data on age-standardized incidence rates, DALYs, and ASDRs. Joinpoint regression was used to examine the trends and annual and average annual percentage changes. We also performed spatial and age-group analyses to explore the differences in disease burden across different geographical and demographic groups.

Findings

In 2021, 32.3 million cases of dengue were reported in South Asia, indicating a 152.9 % increase from 1990. With an estimated annual percentage change of 1.5 %, the ASIR increased from 1141.7 to 1704.9 per 100,000 people. At 944,761, DALYs almost doubled, whereas ASDRs increased at a rate of 1.87 % each year. A total of 28.2 million of these cases were in India, followed by Pakistan and Bangladesh. The increase in dengue cases in India has been reported as 11.2 million in 1990–28.2 million in 2021, with DALYs increasing by 2.86 % annually and an increase in the ASIR of 1.55 %.

Conclusion

The findings highlight a substantial increase in dengue burden across South Asia. The rising burden of incidence and disability requires public health initiatives, such as robust surveillance, targeted vector control, and improved treatment strategies, to reduce its impact effectively.

背景：登革热已成为世界范围内的重大公共卫生问题，特别是在热带和亚热带地区。2000年，全世界报告了505,430例登革热病例，到2023年，病例数已增加到近650万例。本研究旨在利用2021年全球疾病负担数据，研究1990年至2021年南亚国家登革热发病率和残疾调整寿命年的时间趋势，同时确定与地理、性别和年龄相关的差异，特别关注印度的趋势和空间变化。方法：使用GBD 2021数据库提取年龄标准化发病率、DALYs和asdr数据。联结点回归用于检验趋势和年度和平均年度百分比变化。我们还进行了空间和年龄组分析，以探讨不同地理和人口群体之间疾病负担的差异。研究结果：2021年，南亚报告了3230万登革热病例，比1990年增加了152.9 %。估计每年的百分比变化为1.5 %，ASIR从每10万人1141.7增加到1704.9。DALYs为944,761，几乎翻了一番，而asdr每年以1.87 %的速度增长。其中2820万例发生在印度，其次是巴基斯坦和孟加拉国。据报告，印度登革热病例在1990年至2021年期间增加了1120万例，至2820万 万例，伤残调整生命年每年增加2.86 %，ASIR增加1.55 %。结论：研究结果突出了南亚地区登革热负担的大幅增加。发病率和残疾负担日益加重，需要采取公共卫生举措，如强有力的监测、有针对性的病媒控制和改进的治疗战略，以有效减少其影响。

{"title":"Trends in dengue incidence and disease burden in South Asia with special reference to India: Insights from the global burden of disease data, 1990–2021","authors":"Ravichandiran Velayutham , Sheetal Kalra , Sheetal Yadav , Abhishek Dadhich , Prabodh Chander Sharma , Sapna Yadav , Palka Mittal , Aditya Kukreti , Priyansh Ajmera , Puneeta Ajmera , Mohammad Miraj , Riyaz Ahamed Shaik , Abeer Al-Maamari","doi":"10.1016/j.jiph.2026.103142","DOIUrl":"10.1016/j.jiph.2026.103142","url":null,"abstract":"<div><h3>Background</h3><div>Dengue fever has become a significant public health issue worldwide, especially in tropical and subtropical regions. In 2000, 505,430 cases of dengue were reported worldwide, and by 2023, the number of cases had increased to nearly 6.5 million. The present study aims to examine the temporal trends in dengue incidence and disability-adjusted life years from 1990 to 2021 using Global Burden of Disease 2021 data across South Asian countries while identifying geographic, gender, and age-related disparities with a specific focus on trends and spatial variations in India.</div></div><div><h3>Methods</h3><div>The GBD 2021 database was used to extract data on age-standardized incidence rates, DALYs, and ASDRs. Joinpoint regression was used to examine the trends and annual and average annual percentage changes. We also performed spatial and age-group analyses to explore the differences in disease burden across different geographical and demographic groups.</div></div><div><h3>Findings</h3><div>In 2021, 32.3 million cases of dengue were reported in South Asia, indicating a 152.9 % increase from 1990. With an estimated annual percentage change of 1.5 %, the ASIR increased from 1141.7 to 1704.9 per 100,000 people. At 944,761, DALYs almost doubled, whereas ASDRs increased at a rate of 1.87 % each year. A total of 28.2 million of these cases were in India, followed by Pakistan and Bangladesh. The increase in dengue cases in India has been reported as 11.2 million in 1990–28.2 million in 2021, with DALYs increasing by 2.86 % annually and an increase in the ASIR of 1.55 %.</div></div><div><h3>Conclusion</h3><div>The findings highlight a substantial increase in dengue burden across South Asia. The rising burden of incidence and disability requires public health initiatives, such as robust surveillance, targeted vector control, and improved treatment strategies, to reduce its impact effectively.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"19 4","pages":"Article 103142"},"PeriodicalIF":4.0,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146156991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

USING GLOBAL SEQUENCE DATABASES TO INFORM AND ACCELERATE ASSAY DEVELOPMENT OF RAPID TESTS FOR NEISSERIA GONORRHOEAE ANTIMICROBIAL RESISTANCE 利用全球序列数据库为淋病奈瑟菌抗微生物药物耐药性快速检测提供信息并加快检测方法的开发

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103100

Abdulrahman Ayfan , Leah Roberts , David Whiley

引用次数: 0

EFFICACY OF NOVEL ΒETA-LACTAMASE INHIBITOR COMBINATIONS AGAINST MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA FROM THE UNITED ARAB EMIRATES 新型Βeta-lactamase抑制剂组合对来自阿拉伯联合酋长国的多重耐药革兰氏阴性菌的疗效

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103098

Mansour Aljneibi, Mohammad AlAwadi, Mohammed AlManssori, Nouf Masood, Amna Alhashmi, Maitha Alshamsi, Fatima Alsaedi, Farah Alnaqbi, Mariam Adi, Ali Alnuaimi, Akela Ghazawi, Farah Al-Marzooq

引用次数: 0

Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A call for global surveillance and coordinated action 高毒力和耐碳青霉烯肺炎克雷伯菌：呼吁全球监测和协调行动。

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2026.103141

Shital Ghogale, Ketaki Pathak

引用次数: 0

PREVALENCE OF HIGH-RISK CLONES OF KLEBSIELLA PNUEMONIAE IN THE UAE AND ASSOCIATION WITH RESISTANCE AND VIRULENCE 阿联酋肺炎克雷伯菌高危克隆的流行及其与耐药性和毒力的关系

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103097

Lana Daoud, Akela Ghazawi, Farah Al-Marzooq

引用次数: 0

SURGICAL GURARDING INFECTION RISK SCORE (SGIRS) TO REDUCE THE INCIDENCE OF SURGICAL SITE INFECTION AMONGST LSCS PATIENT OUTCOMES AND BEST PRACTICES 手术保护感染风险评分（sgirs）减少LSCS患者手术部位感染发生率的结果和最佳实践

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103096

Zizi Wanis , Salam Alhasani , Amr Elmekresh

引用次数: 0

COMPREHENSIVE GENOMIC ANALYSIS OF VANCOMYCIN- AND DAPTOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM BACTEREMIA IN A HIGH-RISK PATIENT 1例高危患者万古霉素和达托霉素耐药粪肠球菌菌血症的综合基因组分析

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103102

Akela Ghazawi , Ashrat Manzoor , Maryam AlAzri , Noura AlNuaimi , Ahmed Al Hammadi , Mushtaq Khan

引用次数: 0

ANALYSIS OF THE RESISTOME OF MULTI-DRUG RESISTANT GRAM-NEGATIVE PATHOGENS ISOLATED FROM PATIENTS WITH BACTERIAL PNEUMONIA 细菌性肺炎患者多重耐药革兰氏阴性病原菌的耐药性分析

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health

Pub Date : 2026-01-08 DOI: 10.1016/j.jiph.2025.103094

Al Marzooq F , Al Ali N , Ahmed Y , Akhter I , Jog S , Nabi A , Ayoub Moubareck C

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Infection and Public Health

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀